Discussions on Diversity: Patient Diversity in Clinical Trials
Listening and learning from patients and physicians about critical barriers to accessing clinical research and ways to overcome them.
Watch VideoListening and learning from patients and physicians about critical barriers to accessing clinical research and ways to overcome them.
Watch VideoThrough these series of reports, we will share feedback from both our quantitative and qualitative research sources to support greater understanding of the need for patient diversity in clinical trials and highlight areas for action.
Discussion Chapters
Discussion on Diversity reports provide in-depth, expert insight from a range of seasoned professionals with extensive knowledge about life sciences, patient advocacy, and diversity, equity, and inclusion in healthcare.
The purpose of the report is to speak to people from these diverse communities, understand the barriers, understand the challenges in regard to research, and get their feedback and their input about ways to overcome them. By working with people to listen, understand, and ensure that we are giving equitable access to clinical research and making sure that our study population is reflective of diverse populations. By working with these patient communities and sites, we can then build a roadmap for the particular services and tools to be successful. Through these reports, Parexel intends to support sponsors, even our competitors, and the industry at large to make sure that we're designing more inclusive clinical trials the prioritize safety and efficacy.
Our Research Methods
Hosted semi-structured roundtables with Black, Latinx, Asian, transgender and non-binary members of Parexel’s Patient Advisory Councils in Australia, Germany, Italy, UK and US.
Held in-depth discussions with medical professionals across US and Canada.
Received input from 1,945 respondents across a broad range of racial and ethnic groups in Australia, Canada, France, Hungary, Italy, Mexico, Poland, Spain, UK and US.
Conducted interviews with Black, Latinx and Asian members of the UK and US public.
Conducted a series of scientific literature searches for articles published from January 2018 to July 2022 that specifically mentioned transgender or non-binary patients.
The contents of this report are the opinions of third parties derived from surveys, focus group sessions, interviews and patient advisory group meetings and do not reflect the opinions or positions of Parexel or its affiliates.